[Acquired factor V inhibitor: etiology, bleeding risk and therapeutic management with regard to three cases]

@article{citeulike:240377, abstract = {INTRODUCTION: Acquired factor V inhibitor is rare and clinical symptoms are quite variable. Bleeding is the leading symptom but some patients are asymptomatic. Several diseases or conditions are associated with factor V inhibitors. Various treatments have been attempted but randomized or prospective trials are not available. EXEGESIS: Here we report three cases of acquired factor V inhibitor. These reports highlight the clinical variability of this disorder. Pathogenesis and therapy with reference to the literature are discussed. CONCLUSION: Factor V inhibitors are rare and associated to several diseases or conditions. Pathogenesis is still unclear except in patients exposed to bovine thrombin. The majority of the cases developed after surgery. In a few cases there is an association to a malignant or autoimmune disease. Plasmapheresis and platelet transfusions might be the best treatment in case of severe bleeding. High-dose intravenous immunoglobulin infusions have been used successfully in some cases and we report here their efficacy in two cases.}, address = {Service de m\'{e}decine interne, h\^{o}pital de la Conception, 13385 Marseille, France. nschleinitz@mail.ap-hm.fr}, author = {Schleinitz, N. and Veit, V. and Chouquet, D. and Seux, V. and Arnoux, D. and Mokart, D. and Lelong, B. and Alessi, M. C. and Kaplanski, G. and Harl\'{e}, J. R. }, citeulike-article-id = {240377}, issn = {0248-8663}, journal = {Rev Med Interne}, month = {November}, number = {11}, pages = {1119--1123}, posted-at = {2005-06-29 17:20:03}, priority = {2}, title = {[Acquired factor V inhibitor: etiology, bleeding risk and therapeutic management with regard to three cases]}, url = {http://view.ncbi.nlm.nih.gov/pubmed/11817124}, volume = {22}, year = {2001} }

TY - JOUR ID - citeulike:240377 L3 - citeulike-article-id:240377 TI - [Acquired factor V inhibitor: etiology, bleeding risk and therapeutic management with regard to three cases] JF - Rev Med Interne VL - 22 IS - 11 SP - 1119 EP - 1123 AD - Service de médecine interne, hôpital de la Conception, 13385 Marseille, France. nschleinitz@mail.ap-hm.fr SN - 0248-8663 N2 - INTRODUCTION: Acquired factor V inhibitor is rare and clinical symptoms are quite variable. Bleeding is the leading symptom but some patients are asymptomatic. Several diseases or conditions are associated with factor V inhibitors. Various treatments have been attempted but randomized or prospective trials are not available. EXEGESIS: Here we report three cases of acquired factor V inhibitor. These reports highlight the clinical variability of this disorder. Pathogenesis and therapy with reference to the literature are discussed. CONCLUSION: Factor V inhibitors are rare and associated to several diseases or conditions. Pathogenesis is still unclear except in patients exposed to bovine thrombin. The majority of the cases developed after surgery. In a few cases there is an association to a malignant or autoimmune disease. Plasmapheresis and platelet transfusions might be the best treatment in case of severe bleeding. High-dose intravenous immunoglobulin infusions have been used successfully in some cases and we report here their efficacy in two cases. AU - Schleinitz, N AU - Veit, V AU - Chouquet, D AU - Seux, V AU - Arnoux, D AU - Mokart, D AU - Lelong, B AU - Alessi, MC AU - Kaplanski, G AU - Harlé, JR PY - 2001/11// UR - http://view.ncbi.nlm.nih.gov/pubmed/11817124 ER -